PMV Pharmaceuticals Management
Management criteria checks 3/4
PMV Pharmaceuticals' CEO is David Mack, appointed in Jul 2013, has a tenure of 11.33 years. total yearly compensation is $2.21M, comprised of 26.5% salary and 73.5% bonuses, including company stock and options. directly owns 1.25% of the company’s shares, worth $1.04M. The average tenure of the management team and the board of directors is 3.7 years and 3.8 years respectively.
Key information
David Mack
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 26.5% |
| CEO tenure | 11.3yrs |
| CEO ownership | 1.3% |
| Management average tenure | 3.7yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?
Aug 04
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Apr 20Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Dec 22We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth
Sep 08Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
May 10PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
Jan 11Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Sep 22PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04
Aug 09PMV Pharma joins Merck to study lead candidate with Keytruda
Jul 18Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Jun 09Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Feb 23Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Nov 05Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Jul 23PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business
Apr 09Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?
Dec 25PMV Pharmaceuticals reports Q3 results
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$51m |
| Jun 30 2024 | n/a | n/a | -US$49m |
| Mar 31 2024 | n/a | n/a | -US$65m |
| Dec 31 2023 | US$2m | US$586k | -US$69m |
| Sep 30 2023 | n/a | n/a | -US$73m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$74m |
| Dec 31 2022 | US$4m | US$564k | -US$73m |
| Sep 30 2022 | n/a | n/a | -US$72m |
| Jun 30 2022 | n/a | n/a | -US$69m |
| Mar 31 2022 | n/a | n/a | -US$65m |
| Dec 31 2021 | US$4m | US$545k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$50m |
| Jun 30 2021 | n/a | n/a | -US$44m |
| Mar 31 2021 | n/a | n/a | -US$39m |
| Dec 31 2020 | US$1m | US$495k | -US$34m |
| Sep 30 2020 | n/a | n/a | -US$31m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$27m |
| Dec 31 2019 | US$628k | US$461k | -US$25m |
Compensation vs Market: David's total compensation ($USD2.21M) is above average for companies of similar size in the US market ($USD650.80K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Mack (62 yo)
11.3yrs
Tenure
US$2,209,795
Compensation
Dr. David H. Mack, Ph D., Co-founded PMV Pharmaceuticals, Inc. in 2013 and also serves as its President and Chief Executive Officer since July 2013. Dr. Mack joined the PMV Pharmaceuticals, Inc. in 2013.D...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$2.21m | 1.25% $ 1.0m | |
| Co-Founder | 11.8yrs | US$220.27k | 0.79% $ 659.8k | |
| Chief Development Officer | 5.4yrs | US$1.10m | 0.044% $ 36.6k | |
| Chief Financial Officer | less than a year | no data | 0.012% $ 9.9k | |
| General Counsel | 4.3yrs | no data | no data | |
| Senior VP and Head of Corporate Development & Investor Relations | 3.2yrs | no data | no data | |
| Vice President of Human Resources | 1.8yrs | no data | no data | |
| Senior Vice President of Drug Discovery & CMC | no data | no data | no data | |
| Senior VP and Head of Clinical Development & Medical Affairs | 1.5yrs | no data | no data | |
| VP & Head of Clinical Operations | no data | no data | no data |
3.7yrs
Average Tenure
62yo
Average Age
Experienced Management: PMVP's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.4yrs | US$2.21m | 1.25% $ 1.0m | |
| Co-Founder | 11.4yrs | US$220.27k | 0.79% $ 659.8k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 2yrs | US$124.27k | no data | |
| Independent Chairman of the Board of Directors & Member of Scientific Advisory Board | 4.4yrs | US$176.77k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director & Chair of Clinical Advisory Board | 3.6yrs | US$133.27k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$140.27k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$127.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data |
3.8yrs
Average Tenure
63.5yo
Average Age
Experienced Board: PMVP's board of directors are considered experienced (3.8 years average tenure).